Not medical advice. Cagrilintide is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.
Cagrilintide is listed in our catalogue under “Metabolic / Fat Loss.” In scientific publications it is discussed in technical language; this page translates the general themes into everyday wording while staying faithful to research-only framing.
One-paragraph overview from our research datasheet — still scientific, but faster to read than the full mechanism list below.
Cagrilintide (AM833), long-acting acylated amylin analogue and non-selective AMYR/CTR agonist with 8-day half-life for once-weekly obesity research.
Peer-reviewed literature typically discusses Cagrilintide in specific experimental settings. The points below reflect how the scientific community frames this compound—not as health claims, but as the research questions being asked.
Research vs. personal use: Literature describes experiments in controlled lab and animal models. This is distinct from any real-world use; our products are for laboratory research only.
Metabolic peptides in this category are investigated for appetite signalling, incretin pathways, and energy balance in research models. Literature emphasises mechanisms rather than lifestyle advice.
Our datasheet lists mechanistic themes observed in preclinical work. These are research endpoints, not health claims. They help scientists understand and compare pathways.
Storage requirements: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. · Learn best practices in our detailed storage guide.
Research dosing context: Literature typically discusses 0.25–2.4 mg subcutaneously (dose escalation) · Once weekly subcutaneous injection · t½ = 159–195 h (~8 days); Tmax = 24–72 h (median); albumin binding via C20 fatty diacid (analogous to Semaglutide); dose escalation: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg, each maintained 4 weeks. CagriSema uses co-formulated 2.4/2.4 mg in single injection. Currently in late-phase clinical trials.
Preparation steps: Follow our detailed reconstitution guide, use the calculator tool for volume confirmation, and always verify purity with the COA reading guide.
GLP-1 agonists activate the GLP-1 receptor. Cagrilintide activates the amylin receptor family (AMY1/2/3R) plus the calcitonin receptor. The two pathways engage different appetite circuits, which is why combining them (as in CagriSema research) produces larger effects than either alone.
Native human amylin forms amyloid fibrils that are toxic to pancreatic islet cells and make the peptide impractical for sustained research use. Substituting prolines at positions 25, 28, and 29 (borrowed from rat amylin, which does not aggregate) blocks the fibrillation pathway.
Keep the lyophilised powder at −20 °C in the freezer. After reconstitution with bacteriostatic water, refrigerate at 1-6 °C and protect from light. Avoid repeated freeze-thaw cycles, which can damage the fatty acid tail.
It depends on the peptide class. Cagrilintide is a long-acting amylin analogue studied for appetite and metabolic research, often alongside GLP-1 peptides. As with the GLP-1 class, the research literature on appetite-regulating peptides indicates the appetite effects depend on continued receptor stimulation, so they wane once administration stops and the compound clears; cagrilintide's long half-life means that clearance is gradual. These observations come from research and clinical studies — cagrilintide here is an unapproved research-grade peptide for laboratory research only and not for human use.
No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.
Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.
Other compounds researchers often read about alongside Cagrilintide.
Primary literature and registries for Cagrilintide, plus mainstream coverage of the peptide category. Research use only - not medical advice.
Databases & literature:
Peptides in the news:
Access concentration, batch info, variants, and current pricing on our shop.
Also known as: Cagrilintide, Cagrilintide Acetate, Long-Acting Amylin Analogue, Amylin Analogue Research Peptide